AIM: This study examined the efficacy of sertindole in comparison with a selective 5-HT(6) and a 5-HT(2A) receptor antagonist to reverse sub-chronic phencyclidine (PCP)-induced cognitive deficits in female rats. METHODS: In the first test, adult female hooded Lister rats were trained to perform an operant reversal learning task to 90% criterion. After training, rats were treated with PCP at 2 mg/kg (i.p.) or vehicle twice daily for 7 days, followed by 7 days washout. For the second test, novel object recognition (NOR), a separate batch of rats, had the same sub-chronic PCP dosing regime and washout period. In reversal learning, rats were treated acutely with sertindole, the selective 5-HT(2A) receptor antagonist M100.907 or the selective 5-HT(6) receptor antagonist SB-742457. RESULTS: The PCP-induced selective reversal learning deficit was significantly improved by sertindole, M100.907 and SB-742457. Sertindole also significantly improved the sub-chronic PCP-induced deficit in NOR, a test of episodic memory following a 1 min and 1 h inter-trial interval. In vivo binding studies showed that the dose-response relationship for sertindole in this study most closely correlates with affinity for 5-HT(6) receptor in vivo binding in striatum, although contribution from binding to 5-HT(2A) receptors in vivo in cortex may also provide an important mechanism. CONCLUSION: The efficacies of selective 5-HT(2A) and 5-HT(6) receptor antagonists suggest potential mechanisms mediating the effects of sertindole, which has high affinity for these 5-HT receptor subtypes. The sertindole-induced improvement in cognitive function in this animal model suggests relevance for the management of cognitive deficit symptoms in schizophrenia.
AIM: This study examined the efficacy of sertindole in comparison with a selective 5-HT(6) and a 5-HT(2A) receptor antagonist to reverse sub-chronic phencyclidine (PCP)-induced cognitive deficits in female rats. METHODS: In the first test, adult female hooded Lister rats were trained to perform an operant reversal learning task to 90% criterion. After training, rats were treated with PCP at 2 mg/kg (i.p.) or vehicle twice daily for 7 days, followed by 7 days washout. For the second test, novel object recognition (NOR), a separate batch of rats, had the same sub-chronic PCP dosing regime and washout period. In reversal learning, rats were treated acutely with sertindole, the selective 5-HT(2A) receptor antagonist M100.907 or the selective 5-HT(6) receptor antagonist SB-742457. RESULTS: The PCP-induced selective reversal learning deficit was significantly improved by sertindole, M100.907 and SB-742457. Sertindole also significantly improved the sub-chronic PCP-induced deficit in NOR, a test of episodic memory following a 1 min and 1 h inter-trial interval. In vivo binding studies showed that the dose-response relationship for sertindole in this study most closely correlates with affinity for 5-HT(6) receptor in vivo binding in striatum, although contribution from binding to 5-HT(2A) receptors in vivo in cortex may also provide an important mechanism. CONCLUSION: The efficacies of selective 5-HT(2A) and 5-HT(6) receptor antagonists suggest potential mechanisms mediating the effects of sertindole, which has high affinity for these 5-HT receptor subtypes. The sertindole-induced improvement in cognitive function in this animal model suggests relevance for the management of cognitive deficit symptoms in schizophrenia.
Authors: D L Zimbroff; J M Kane; C A Tamminga; D G Daniel; R J Mack; P J Wozniak; T B Sebree; B A Wallin; K B Kashkin Journal: Am J Psychiatry Date: 1997-06 Impact factor: 18.112
Authors: Patricia S Goldman-Rakic; Stacy A Castner; Torgny H Svensson; Larry J Siever; Graham V Williams Journal: Psychopharmacology (Berl) Date: 2004-04-30 Impact factor: 4.530
Authors: Milena Girotti; Samantha M Adler; Sarah E Bulin; Elizabeth A Fucich; Denisse Paredes; David A Morilak Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2017-07-06 Impact factor: 5.067
Authors: John P Redrobe; Lisbeth Elster; Kristen Frederiksen; Christoffer Bundgaard; Inge E M de Jong; Garrick P Smith; Anne Techau Bruun; Peter H Larsen; Michael Didriksen Journal: Psychopharmacology (Berl) Date: 2011-11-29 Impact factor: 4.530
Authors: Sanna K Janhunen; Heta Svärd; John Talpos; Gaurav Kumar; Thomas Steckler; Niels Plath; Linda Lerdrup; Trine Ruby; Marie Haman; Roger Wyler; Theresa M Ballard Journal: Psychopharmacology (Berl) Date: 2015-06-14 Impact factor: 4.530
Authors: Jared W Young; J David Jentsch; Timothy J Bussey; Tanya L Wallace; Daniel M Hutcheson Journal: Neurosci Biobehav Rev Date: 2012-10-12 Impact factor: 8.989
Authors: Maria Rosaria A Muscatello; Antonio Bruno; Gianluca Pandolfo; Umberto Micò; Salvatore Settineri; Rocco Zoccali Journal: Drug Des Devel Ther Date: 2010-09-07 Impact factor: 4.162
Authors: John P Redrobe; Morten Jørgensen; Claus T Christoffersen; Liliana P Montezinho; Jesper F Bastlund; Martin Carnerup; Christoffer Bundgaard; Linda Lerdrup; Niels Plath Journal: Psychopharmacology (Berl) Date: 2014-03-01 Impact factor: 4.530